Cargando…
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
The development of checkpoint inhibitors has changed the treatment paradigm for cancer. Checkpoint inhibitors nivolumab, pembrolizumab, and cemiplimab target programmed death-1 (PD-1), whereas durvalumab, avelumab, and atezolizumab target PD-ligand 1. Ipilimumab targets cytotoxic T lymphocyte–associ...
Autores principales: | Bukamur, Hazim, Katz, Heather, Alsharedi, Mohamed, Alkrekshi, Akram, Shweihat, Yousef R., Munn, Nancy J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587235/ https://www.ncbi.nlm.nih.gov/pubmed/33140115 http://dx.doi.org/10.14423/SMJ.0000000000001166 |
Ejemplares similares
-
Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II
por: Bukamur, Hazim, et al.
Publicado: (2021) -
Nivolumab-induced Third Degree Atrioventricular Block in a Patient with Stage IV Squamous Cell Lung Carcinoma
por: Bukamur, Hazim S, et al.
Publicado: (2019) -
Iatrogenic esophageal and tracheal perforation with tracheoesophageal fistula following emergency intubation
por: Alkrekshi, Akram, et al.
Publicado: (2020) -
The role and safety of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis and management of infected bronchogenic mediastinal cysts in adults
por: Bukamur, Hazim S., et al.
Publicado: (2018) -
Effects of Long-Term Combination LT4 and LT3 Therapy for Improving Hypothyroidism and Overall Quality of Life
por: Tariq, Anam, et al.
Publicado: (2018)